

How have surrogate outcomes been dealt with in existing HTA evaluations by different HTA bodies and what lessons can be learnt?


Laura Flight¹, Fatima Salih¹, Zoe Garrett¹, Shane Collins¹, Phyto Aung², Michael Coory², Daniel Ollendorf³, Marina Richardson³, Dalia Dawoud¹

¹ National Institute for Health and Care Excellence ² Australian Government Department of Health and Aged Care ³ Institute for Clinical and Economic Review


Background

- Surrogate outcomes pose challenges to health technology assessment (HTA) bodies and payers when used to inform the clinical and cost-effectiveness of technologies
- Some HTA bodies have published methodological guidance on the use and validation of surrogates
- It is not uncommon that decision makers must make recommendations in the absence of well-established evidence on the validation of surrogates

What we did



Key themes



What we learnt

- Decision making using surrogates is a frequent and challenging problem faced by HTA bodies globally
- This work informed a wider project aimed at developing recommendations and considerations for the use of surrogates in economic modelling for HTAs

For further information please visit:

<https://www.nice.org.uk/news/blogs/how-surrogate-outcomes-influence-long-term-health-outcomes>



Laura Flight
Scientific Adviser
National Institute for Health and Care Excellence
Email: laura.flight@nice.org.uk